The first descriptions of endovascular repair of abdominal aortic aneurysms (AAAs) occurred in the late 1980s 1 and early 1990s. 2 Twenty years later, endovascular aneurysm repair (EVAR) accounted for more than three quarters of elective aneurysm repairs among Medicare beneficiaries in the United States. 3 The rapidity with which this technology was adopted into clinical practice is notable and may relate to the favorable outcomes observed with this minimally invasive strategy. Several studies, including prospective randomized controlled trials and retrospective reviews of administrative data, all confirmed an early morbidity and mortality benefit with EVAR compared with open repair. [4] [5] [6] However, certain anatomic considerations preclude the use of EVAR. Short-neck infrarenal and juxtarenal AAA are not amenable to durable repair with conventional EVAR devices. [7] [8] [9] Efforts to offer an endovascular option for these anatomically unfit patients have resulted in the development of several novel approaches. Fenestrated endografts, designed to extend the seal zone above the renal arteries, were first described in the late 1990s. [10] [11] [12] A commercially available option was studied in the United States in 2009, 13 with favorable technical results and patient outcomes. 14 This device, the Zenith fenestrated endovascular grafts (ZFEN) for AAA (Cook Medical, Bloomington, Ind), gained Food and Drug Administration (FDA) approval in the United States in April 2012. At the time of this report, it remains the only commercially available fenestrated device, in the United States, for treatment of short-neck and juxtarenal AAA. Although a number of published reports of fenestrated EVAR have indicated favorable outcomes, the authors note that these results are contingent upon proper patient selection, thoughtful and extensive preoperative planning, and refinement of advanced endovascular skills. 14, 15 Thorough training is critical to ensure the safe and effective use of these devices. Given the complexity of these fenestrated EVAR repairs, we sought to evaluate patterns of ZFEN adoption at the physician and hospital level since FDA approval in 2012.
METHODS
Datasets. Data were obtained from Cook Medical and included physician training records and orders placed for ZFEN devices in the United States from April 2012 (first order dated June 22, 2012) through August 31, 2015. Since the time of FDA approval, any physician in the United States wishing to order a ZFEN device is mandated to attend a formal 1-2 day training session and to have a minimum of two ZFEN cases proctored by an experienced fenestrated physician.
The physician training and device order sets were based on sales data. The training log dataset contained information on the date of training, number of physicians trained, and the city and state of the training. All physician data were deidentified, and each physician was assigned a random identification number. The device order log dataset contained date of order, a unique order number, diameter and lengths of the devices ordered, the hospital name, and the deidentified surgeon identification number. Hospital names were deidentified also. Although the dataset does not contain information at the hospital system level or practice group level, additional analyses were performed at the individual hospital level to account for the possibility that a hospital has one only physician designated to place orders, despite multiple physicians using the devices. The device design dataset was derived from manufacturing data and contained information for each device pertaining to the number of small fenestrations, large fenestrations, and scallops used.
Device orders. The unit of analysis was the order number, to which all components in a given order were assigned; orders with two components were considered one single device order. Hospital names were used to designate institutions as teaching or nonteaching, in accordance with the Association of American Medical Colleges' definition. 16 Geographic region was defined in accordance with the U.S. Census Bureau. 17 Device design details. The number of small fenestrations, large fenestrations, and scallops on each unique fenestrated component was provided. This information was used to define unique device configurations (eg, configuration number 1 equals one scallop and two small fenestrations, configuration number 2 equals two small fenestrations and one large fenestration; refer to the second table in the Results section for complete listing).
Statistical analysis. Counts and percentages were determined for categorical variables. Means and standard deviations were calculated for continuous variables. Analyses were performed at the physician level and at the hospital level. When investigating the change in the number of orders placed per month, linear regression was used to estimate the slope, its 95% confidence interval, and the P value of the estimate. Linear regression was also performed individually on the three time periods of interest (June 2012-April 2013, May 2013-December 2014, and January 2015-August 2015). After excluding physicians whose first order was less than 6 months before the conclusion of the study period, an average number of orders, per physician, per year, was calculated. P values were considered statistically significant at an alpha ¼ 0.05 level. All analyses were conducted using SAS 9.3 (SAS Institute, Cary, NC). components, corresponding to 2669 device orders. Over the study period, devices were ordered more commonly at teaching hospitals (64%; n ¼ 1703), with a relatively uniform distribution across all geographic regions (Table I) .
RESULTS

Physician
The first orders were logged in June 2012, with nine devices ordered that month. In the final month of the study period, there were 91 orders, representing a nine-fold increase in orders per month (Fig 1) . There were 166 devices ordered in the first 6 months after FDA approval; there were 781 devices ordered in the last 6 months of the study period. The slope (rate of rise) of orders per month over the total study period was positive 2.3 orders per month (Fig 2) . When the study period was divided into three discrete periods (period 1, June 2012 to April 2013; period 2, May 2013 to December 2014; period 3, January 2015 to August 2015), the rate of rise was greatest in period 1 at positive 4.1 orders per month, then decreased to positive 1.7 orders per month in period 2, and was not significantly changed over period 3.
The number of physicians ordering ZFEN devices per month increased from eight in June 2012, to a maximum of 76 in July 2015 (Fig 3) . This distribution is not linear. The distribution of the number of devices ordered per physician ranged from 0 to 77 (Fig 4) . There were 165 (30%) trained physicians who have not ordered a device; there were 28 (5%) physicians who have ordered more than 20. Among those physicians who have ordered any devices, the most common number of device orders was two to five orders (n ¼ 144; 26%). When analyzed at the hospital level, rather than the physician level, a similar pattern was seen, with a wide distribution in the number of device orders per hospital, ranging from 0 to 87 (Fig 5) . Among 246 hospitals with an ordering physician, 109 hospitals (44%) placed 10 or fewer orders.
In light of the fact that there was an increase seen in both grafts ordered and physicians trained over time, we accounted for different lengths of time that physicians had access to order a device, to calculate the (Fig 6) . In addition, we determined the number of orders per month, divided by the number of trained physicians per month for each month of the data. Although very gradual, there is a significant increase seen, per trained physician, per month in the number of orders (Fig 7) .
Device design details. Device design details were provided for 2750 orders. Of these 2750 orders, 81 were excluded for falling outside of the prespecified study period. Of the remaining 2669 orders, 51 (2%) were excluded because of missing data related to the number of fenestrations included. The final study cohort included 2618 orders. There were a total of 14 device configurations ordered (Table II) . The most common configuration was two small fenestrations and one scallop (n ¼ 1443, 55%), followed by two small fenestrations and one large fenestration (n ¼ 568, 22%). The majority of devices were designed for three target arteries (79%) (Fig 8) . The average number of target arteries included per design was 2.7 per device.
DISCUSSION
Since the ZFEN device gained FDA approval in April of 2012, there has been a dramatic increase in the number of orders per month, although analysis of the slope of this line suggests there may be a plateau over the last 8-month period of the study. In addition, the number of physicians ordering devices each month has been increasing, and the pattern of adoption includes both teaching and nonteaching hospitals, across all regions of the country. Although these findings suggest there is a widespread interest in this technology across many hospital types and locations, the data suggest that the utilization, at the physician level, is not uniformly distributed. Nearly one-third of trained physicians have not ordered a device, and of ordering physicians, the most common number of ordered devices is between two and five. On an annualized basis, the average number 1  34  86  132  180  200  242  76  141  183  213  246  84  138  41  167  104  230  124  21  207  87  202  54  11  244  158  57  153  108  168  173  135  63  231  219 Number of devices ordered Hospital ID of ZFEN orders per physician is three, with only three physicians who average >20 orders per year. The reasons for this skewed utilization are not known. Although this could reflect that short neck infrarenal and juxtarenal aneurysms are simply far less common than infrarenal aneurysms, and, therefore, a smaller number of physicians have performed these repairs. Other contributing factors may include the technical complexity associated with execution of this advanced endovascular procedure. In contrast to infrarenal EVAR, which is now often planned quickly and accurately even in the setting of ruptured AAA, the technical success of fenestrated aneurysm repair is contingent upon meticulous preoperative planning. Steps include processing axial computed tomographic images in software capable of generating three-dimensional models and enabling centerline measurements, then carefully measuring, by hand, the exact locations of the target vessels. The anatomy must be scrutinized to ensure that a ZFEN device is appropriate, and then the exact configuration must be chosen. There are manufacturing restrictions that must be considered as well (listed at: https://fencheck.cookmedical.com). The planning physician must have a solid command of endovascular principles to understand many factors such as how the device will behave with tortuosity of access vessels, how the diameter of the aorta at the level of the target vessels will impact the success of cannulation through the partially constrained device, and how stent grafts will track into target arteries. Also, although not an absolute necessity, there are innumerable benefits to performing these procedures in hybrid operating rooms, equipped with modern imaging systems, capable of fusion technology. A highly skilled operating room team, with a large inventory of ancillary endovascular equipment is also desirable. Even postoperative care is greatly facilitated by close collaboration with a strong noninvasive vascular laboratory, capable of performing accurate and thorough duplex examination of the repair. For all these reasons, 21 The volume-outcome relationship has been well described for a number of procedures spanning not only vascular surgery, but orthopedic, cardiac surgery, general, transplant, and oncologic surgery as well. 20, [22] [23] [24] [25] [26] [27] [28] Unlike these procedures, fenestrated aneurysm repair in the United States is contingent upon access to a custom-ordered device. This creates a considerable dilemma for device manufacturers who want to sell devices, but who are also committed to training physicians to use the devices safely to achieve excellent patient outcomes. Mandatory training courses, such as those required for access to the ZFEN device, are aimed at ensuring that this balance is achieved. Another unknown is the number of cases which must be performed to achieve proficiency with ZFEN, or other complex EVAR. Greenberg et al 13 and Oderich et al 14 noted
several lessons learned that resulted in refinements in planning and technique with ZFEN; but an exact number of cases at which proficiency is achieved is not reported. We also do not know the requisite annual volume of cases that translates into better outcomes. In the case of pancreatectomy, McPhee et al 27 were able to suggest hospital volume cut-points, associated with different hazards of perioperative mortality. This study, however, drew from the Nationwide Inpatient Sample database, containing nearly 300,000 patient-discharges. A similar dataset for ZFEN does not exist currently. There are several important limitations inherent to this analysis, namely that there are no patient-level data available. Therefore, we are unable to make any comment on the outcomes associated with these procedures. Also, the number of devices that were ordered, but ultimately not implanted, is unknown. The technical success of implantation is also unknown. For all of these reasons, we are unable to make any attempt to correlate surgeon order volume with outcomes. In addition, the order log may misattribute orders to a single "lead surgeon" at an institution where, in reality, other members of the group may be ordering and placing ZFEN devices. However, if there is a lead surgeon, this may reflect a team approach to complex aneurysm repair, thereby minimizing the impact of such misattribution. We are also unable to identify if there are particular characteristics associated with those physicians who were trained but have not ordered any devices. Finally, there may also be error in the calculation of target arteries, if alternative measures for preserving branch vessel perfusion are employed (eg, snorkels added to a fenestrated device 29, 30 or physician modification of the graft with creation of extra fenestrations); the database does not provide intraoperative details such as number of target arteries treated by another method. We are also unable to compare outcomes of ZFEN procedures compared with alternative repair strategies for short neck infrarenal and juxtarenal repairs. Another question that cannot be answered by the current analysis is whether this distribution of device orders (a small subset of physicians ordering the majority of the devices, whereas many others are ordering fewer than five per year) mirrors the pattern of open repair of short neck infrarenal and juxtarenal aneurysms at these institutions. If true, that would suggest that these types of repairs are limited to relatively few physicians and hospitals regardless of whether an open or endovascular treatment strategy is chosen.
Despite these limitations, this analysis represents the first attempt to better understand how the adoption of commercially available fenestrated EVAR devices for the treatment of complex aneurysms has proceeded in the United States. Further study is required to better understand the factors that have led to this pattern. In addition, it is important to delineate the clinical impact of this pattern of adoption, in terms of verifying whether a traditional volume-outcome relationship exists for this procedure, as has been observed with other complex surgical procedures. Our data demonstrate that physicians from all over the United States at teaching and nonteaching hospitals have sought out ZFEN training with a steady increase in trainings per month, yet this has not translated into widespread use of the device. There may be many explanations for this slow adoption pattern, many of which cannot be investigated with the current dataset and analysis, but we believe do deserve further study. Regardless, if one assumes that volume, in general, correlates with outcomes, this adoption pattern raises questions whether fenestrated technology should be regionalized to high-volume centers. We acknowledge that this is an assumption and is not directly supported by the current study. However, we contend that it provides justification for rigorous study of such a relationship, to determine the best course of action to ensure optimal patient outcomes in the management of complex aortic disease.
Dr Philip Goodney (Lebanon, NH). Your paradigm of using industry data to study trends in a new procedure is relatively new and I think a great idea and a new way to study an evolving procedure. Can you tell us a little bit about the confidentiality issues? I am sure you had to think about when you were pulling this data. I know when we study Medicare claims, we are very careful that we do not pick cells that are too small, so that Mrs Jones might figure out that she was the one AAA repair done in Wyoming in 2012, and, thus, somehow identify herself. I wonder how you address that. Thank you.
Dr Jessica P. Simons. That is a great point you make. Fortunately, we did not have patient information to worry about disclosing, only deidentified physicians, for whom there are not specific criteria for confidentiality. We were sensitive to that issue, however, and do not report anything at a more granular level than geographic region.
Dr Fabio Verzini (Perugia, Italy). Thanks a lot for your presentation. In Europe, this kind of treatment is a matter of team approach. In your case, the ordering physician may not be the same as the team performing the procedure. Do you have any information about the experience of a single operator/ordering physician vs the team experience? Dr Simons. I think that is an excellent point, and I suspect that that may be the case in some of our data as welldthat there is just one lead physician who takes the role of ordering and then the actual procedure is performed by a team of physicians. In terms of our ability to tease that outdthat was limited; but I am not sure if that detracts so much from the overall message that this is a procedure conducted primarily at dedicated centers with a team approach.
Dr Ronald Dalman (Stanford, Calif). I think it is remarkable that a third of the physicians that have gone through the training have not actually implanted an endograft using this technology. Do you think that trend is going to continue? Do you have any projections about adaptation? I know you talked about regionalization and there is also kind of a flattening of case volume, but do you see any other implications of that observation?
Dr Simons. I suspect that the initial enthusiasm led a lot of physicians to get trained, who then ultimately realized that the patient population suited to ZFEN is somewhat rare, and the actual implementation and performance of these procedures is a bit more challenging than anticipated. We did see that there was sort of a plateauing in the number of devices ordered, and I believe that correlates with the finite population of patients whose anatomy is appropriate for ZFEN. The implication is perhaps that there are not so many of these cases that there could ever be lots of high volume centers, possibly lending support for the regionalization of care.
Dr Yazan Duwayri (Atlanta, Ga). It is concerning that the manufacturer could not track their manufactured devices and provide you with information of whether a device was implanted or not. Don't you think industry should be required to store data about fenestrated device implants and the number and type of visceral branch stents? I think Dr Goodney pointed out that we need to pay attention to HIPAA rules, but it is still essential that we have the ability to track these device implants to assess their long-term performance.
Dr Simons. Ideally, we would have a robust data set that included all sorts of information about patients, devices, and their outcomes to establish strong conclusions about delivery of care; however, I am not sure that is the role of industry, or whether a registry such as Vascular Quality Initiative is better for that purpose.
